CryoLife, Inc. (NYSE:CRY) is set to announce third quarter earning results on Wednesday 4th November 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, CRY to report 3Q20 loss of $ 0.04 per share from revenue of $ 59.24 million.
For the full year, analysts anticipate top line of $ 249.57 million, while looking forward to loss of $ 0.12 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 292.00 million ~ $ 298.00 million, where as bottomline are predicted in a range of $ 0.15 ~ $ 0.17 per share
Click Here For More Historical Outlooks Of CryoLife, Inc.
Previous Quarter Performance
CryoLife, Inc. unfold loss for the second quarter of $ 0.02 per share, from the revenue of $ 53.77 million. Wall street analysts are predicting, CRY to report 2Q20 loss of $ 0.14 per share from revenue of $ 50.47 million. The bottom line results beat street analysts by $ 0.12 or 85.71 percent, at the same time, top line results outshined analysts by $ 3.30 million or 6.54 percent.
Stock Performance
Shares of CryoLife, Inc. traded up $ 0.80 or 4.54 percent on Tuesday, reaching $ 18.42 with volume of 319.70 thousand shares. CryoLife, Inc. has traded high as $ 18.81 and has cracked $ 17.76 on the downward trend
According to the previous trading day, closing price of $ 18.42, representing a 39.51 % increase from the 52 week low of $ 12.63 and a 44.54 % decrease over the 52 week high of $ 31.77.
The company has a market capital of $ 697.34 million and is part of the Healthcare sector and Medical Devices industry.
Conference Call
CryoLife, Inc. will be hosting a conference call at 4:30 PM eastern time on 4th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.cryolife.com
CryoLife, Inc., together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.
